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    Rabbit anti-mouse lymphocyte serum (ALS) was studied in respect to its effect on the 
 hemopoietic stem cell. ALS markedly decreased bone marrow CFU cells in vitro and cir-
 culating CFU cells in vivo but slightly did bone marrow and spleen CFU cells in vivo. 
 Lymphocytes and the hemopoietic stem cells have a common antigen. 
   The existence of the hemopoietic stem cell has been proved functionally but its 
morphological identity has not been unanimously determined. Small lymphocytes,') 
pale transitional lymphocytes,2) monocytoid cells3> and others4> have been put forward 
as candidates of the stem cells. Preliminary studies to contribute to this problem 
were performed in our laboratory by the use of stem cell proliferation after irradiation 
and isogeneic bone marrow transplantation, but the result obtained was not satisfactory. 
As a part of our further studies on this subject we studied the antigenicity of the stem 
cell by the use of rabbit anti-mouse lymphocyte serum (ALS) in view of the claim that 
the stem cell takes a form of lymphocyte. This study will also reveal the hematologi-
cal side effect of ALS other than immunosuppression when ALS is used for prevention 
of rejection of transplanted organs. 
                      MATERIAL AND METHOD 
   The axillary and mesenteric lymph nodes from DDD mice were removed, excised 
with scissors and suspended in Tyrode solution. The lymphocyte suspension was filtered 
through 4 layers of gauze and 2 x 107 cells were mixed with the same volume of 
Freund's complete adjuvant and injected into the footpads and several subcutaneous 
sites of normal rabbits. Four weeks later 3 to 6 x 107 lymph node cells were injected 
intravenously into the same rabbits and these animals were bled seven days later by 
cutting ear veins. This was repeated 3 more times and all the sera obtained were 
pooled and inactivated at 56°C for 30 minutes. The serum then was absorbed with 
DDD mouse erythrocytes until its hemagglutinin titer became less than 22, sterilized 
by the milipore filtration and stored at — 20°C until use. Its lymphoagglutinin and 
lymphocyte cytoxicity titer using the trypanblue dye exclusion method was 25 and 22, 
respectively. The number of hemopoietic stem cells was assayed as the number of 
colony forming units (CFU) in the spleen using Till and McCulloch's technique.5) 
Twelve to 16 month old female DDD mice supplied from The Kyoto University Animal 
Center was irradiated with 700-750R of 60Co gamma-rays followed by transplantation of 
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     isogeneic bone marrow which were variously treated in vitro or in vivo. The source 
     of gamma-rays used was a compact 60Co gamma irradiation facility of The Institute for 
     Chemical Research of Kyoto University.6> Eight days later these mice were sacrificed, 
     the spleens removed and CFU counted with a magnifying glass. Lyophilized guinea 
     pig complement supplied by The Toshiba Chemical Company (lot #693) was used in 
      the experiment. 
                                  RESULT 
     I. The effect of ALS on peripheral leucocyte and lymphocyte counts (Fig. 1). 
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                      Fig. 1. WBC and Lymphocyte Count Following 7 Daily 
                             Administrations of ALS or NRS. 
        One quarter ml permouse of ALS or normal rabbit serum (NRS) was injected 
     subcutaneously daily for 7 days. In the ALS injected mice the peripheral leucocyte count 
     dropped markedly due to the decrease of lymphocyte count. At 5 days the decreased 
     leucocyte count went back to the preinjection level, whereas the lymphocyte count re-
     mained low indicating an increase of neutrophils. At 7 days the increase of neutrophils 
     was more marked and the lymphocyte count was at the preinjection level. In the NRS 
     injected mice the leucocyte as well as lymphocyte count remained essentially the same. 
     ALS has been reported to have stronger immunogenicity than NRS and this appears to 
      be one of the reasons why there was such a difference between the two sera.7,8) 
     II. In vitro effect of ALS on CFU. 
         When mouse bone marrow cells were incubated with ALS in the presence of " com-
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plement at 37°C for 30 minutes, the viability of the cells decreased markedly, whereas 
with NRS this was not observed (Table 1). After incubation the bone marrow cells 
were injected into lethally irradiated isogeneic mice. A decrease of CFU count was 
evident as shown in A of Table 2. Increase of the bone marrow dose three times did 
not materially increase the number of CFU. Eight time increase of incubated trans-
planted bone marrow cells still did not give the same number of CFU as the control 
(Table  4  : A versus C, P<0.05) . In the next experiment the bone marrow cells were 
                       Table 1. In Vitro Effect of ALS. 
         BM cellSerum complementBM cell Viability 
      before incubationafter incub. after incub. 
 A(-)(-) 3.0x10693% 
B(-)0.1 ml 2.889 
CNRS 0.1 ml (-) 3.074 
D 3.5x106 in 0.3m10.1m1 2.574         of Tyrode Solu-
 E tionALS 0.02 ml (-) 1.7+aggl. c. 80 
F0.1 ml 3.513 
GALS 0.1 ml (-) 2.6+aggl. c. 78 
H0.1 ml 2.218 
      3.5 x 106 Bone Marrow cells in Tyrode solution are incubated in siliconized test tubes 
  for 30 minutes at 37°C. 
                  Table 2. In Vitro Effect of ALS on CFU (I). 
       IncubationCells injected Colony countsMean S.D. per host 
  A ALS105 3,1,0,1,0,3,0,1,2,3,0,0 1.17 1.27 
B ALS3 x 105 1,2,2,1,2,0,2,0,3,1,1 1.36 0.92 
C NRS105 24,8,13,15,7,21,17,15,13,12 14.5 5.23 
D 710R irradiated control 0,0,0,0,3,1,0,0,0,00.40 0.96 
  Method of incubation (37°C 30'). 
  A & B : IBM 107 in 1 ml of Tyrode+0.033 ml ALS+0.1 ml complement. 
C : IBM 107 in 1 ml of Tyrode+0.1 ml NRS+0.1 ml complement. 
                 Table 3. In Vitro Effect of ALS on CFU (II). 
         IncubationViabilityCells injected Colony count Mean S.D. after inc. per host 
A x 100 dil. ALS90.5% 105 7,8,9,9,67.8 1.21 
B x 100 dil. Lymph-ab. ALS 92.5105 5,5,12,6,10,6 7.3 2.97 
C x 100 dil. NRS87.5105 15,23,17,7,12,14,16,19,14 15.2 4.46 
D Tyrode81.5105 13,10,15,15,11,12,11,5 11.5 3.59 
E710R irradiated control0 0,0,0,4,00.8 1.79. 
  Method of Incubation (37°C 30'). 
  A : IBM 107 in 1 ml of Tyrode+0.1 ml of x 100 diluted ALS+0.1 ml complement. 
B : IBM 107 in 1 m1 of Tyrode+0.1 ml of x 100 diluted lymphocyte-absorbed ALS+0.1 ml 
      complement. 
  C : IBM 107 in 1 ml of Tyrode+0.1 ml of x 100 diluted NRS+0.1 ml complement. 
  D : IBM 107 in 1 ml of Tyrode+(-)+0.1 ml complement. 
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         incubated with 100 time diluted ALS (final dilution 1000 times). After incubation, cell 
          viability was the same as that of the cells incubated with 100 time diluted NRS. How-
         ever, the CFU count was still significantly less than the control (Table  3  : A versus C, 
P<0.01). This may indicate that decrease in number of CFU by ALS is not solely 
                           Table 4. In Vitro Effect of ALS on CFU (III). 
                      IncubationViability Cells injected Colony count Mean S.D. after inc. per host 
       A ALS26% 8x105  8,6,9,8,3,97.2 2.36 
            B x100 ALS s Compl. 90105 8,9,9,7,11,13,13,10,7 9.6 2.26 
            C x 100 NRS s compl. 86105 8,9,13,10,6,6,6,14,14 9.6 3.21 
       D 740R irradiated control1,11.0 
              Method of Incubation (37° 30'). 
A: IBM 107 in 1 ml of Tyrode+0.1 ml of ALS+0.1 ml complement. 
B: IBM 107 in 1 ml of Tyrode+0.1 m1 of x100 diluted ALS. 
C: IBM 107 in 1 ml of Tyrode+0.1 ml of x100 diluted NRS. 
                                  Table 5. In Vivo Effect of ALS.
                   IBM 
Irra- injectedALSColony count Mean S.D.                diation per 
  mouse  
       A 750R (-) (-)0,4,0,2,0,4,0,0,1 1.1 1.72 
          B 750R 105 (-)15,20,16,11,5,11,18,15,5,16 13.2 5.12 
             C 750R 105 0.25 ml I.P. imm. before IBM 13,8,10,12,10,9,11,5,9 9.8 2.32 
            D 750R 105 0.25 ml I.P. 1 day after IBM 12,16,18,10,14,9,10,14 12.9 3.18 
II 
     A 740R (-) (-)1,2,0,0,00.7 0.90 
         B 740R 105 (-)15,15,18,8,11,5,11,13,8 12.7 4.29 
             C 740R 105 0.25 ml I.P. imm. before IBM 14,9,11,4,8,6,11,12,9,9,7 9.1 2.84 
            D 740R 105 0.25 ml I.P. 1 day after IBM 18,11,15,5,8,6,4,12,14,14,16 11.2 4.77 
III 
                   IBM 
Irra- injectedNRSColony countMean S.D. •diation per 
  mouse  
      A 730R (-) (-)0,1,0,0,0,10.3 0.52 
      B 730R 105 (-)8,6,16,15,910.8 4.43 
            E 730R 105 0.25 ml I.P. imm. before IBM 15,13, 6,12,14,1312.2 3.02
           IV 
                    IBM 
Irra- injectedSerumColony countMean S.D.                diation per 
  mouse  
           A 750R 105IBM0.25 mlI.P.1 daybefore 9 19,18,11,10,17,13,17 14.3 3.96 
          B 750R 105 NRS 0.25 ml I.P.18,16,13,14,18,2016.5 2.66 
          C 750R 105 (-)8,18,12,16,15,17,9,20,12,11 13.8 3.99
    D 750R (-) (-)0,0,0,00 
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                                     Table 6. CFU in the Bone Marrow Afer Injection(s) of ALS. 
       Exp. I One day after a injection of ALS. , 
        Treatment of marrow Nucl. cells inCells injected 
--------------------------------------femoral marrowper hostColony countMean Mean per group S.D. 
        Serum Dose per mouse of the donors 
 1. ALS 0.25 ml I.P. 1. 12.5 x 106105 13,10,14,14,13,10,16 12.9 
                2. 18.5105 13,11,12,13,1312.412.71.73 ri 
   2. ALS 1 ml I.V.16.2105 4,15,13,16,12,14,1512.612.64.07 
  3. NRS 0.25 ml I.P. 1. 18.5105 23,18,20,19,13,17,16 18.0c 
                   2. 20.3105 12,19,19,19,19,17,17,20 17.817.92.47° 
  4. Tyrode 0.25 m1 I.P. 1. 25.0105 17,16,16,13,15,15,15 15.3> 
                  2. 23.0105 15,21,18,14,16,19,15 16.916.12.09w                                                                                                     0)                                                                                                                                             0 
 5. 700R irradiated control0,1,0,31a 
"'Exp .II Oneday after7 dailyinjections.x 
     Treatment of marrow donors Nucl. cells in Cells injected0 
----------------------------- femoral marrowColony countMean Meanper group S.D.o 
            Serum Dose per mouse of the donors       per host`° . 
Exp.1 1. ALS 0.25 m1 S.C. 1. 13.3 x 106 105 24,23,17,18,16,1919.518 .2 3.15m 
             2. 15.0105 20,18,16,14,1516.65' 
       2. NRS 0.25 ml S.C. 1. 11.1105 15,18,19,20,1216.814
.9 4.14rn                              2. 15.0105 15,6,9,11,17,18,19,14,16 13.8 
    720R irradiated control0,0,00 
Exp.2 1. ALS 0.25 ml S.C. 1. 10.311,17,11,13,19,20,16 15.3 10513 .5 3.30                              2
. 12.013,18,10,11,9,11,12,14,12,13 12.3 
        2. NRS 0.25 ml S.C. 1. 13.713,14,16,10,14,14,10,16 13.4
         2. 12.010513.3 2.19                                  14,10,14,1513.3 
    740R irradiated control0,0,0,00
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     due to its cytotoxic antibody or that the stem cells are injuried more readily than the 
 lymphocytes. Lymphocyte-absorbed-ALS whose lymphoagglutinin was decreased to 22 
     still had CFU decreasing ability (Table 3 : B). When bone marrow cells were incubat-
     ed with ALS in the absence of complement a decrease of CFU was not observed sug-
     gesting that complement is necessary for the decrease in number of CFU (Table 4) . 
     III. In vivo effect of ALS on CFU. 
        ALS was injected intraperitoneally one day and immediately before and one day 
     after lethal irradiation and 105 isogeneic bone marrow transplantation (Table 5). Splenic 
     CFU count decreased slightly only when ALS was injected immediately before. This 
     result indicates that the number of CFU cells decreases by an appropriate concentration 
     of ALS while they are circulating but not readily once they enter the spleen. 
     IV. CFU in the bone marrow after injection(s) of ALS. 
        Effect of ALS injection(s) on the number of CFU cells in the femoral marrow was 
     studied. DDD female mice were injected with 0.25 ml of ALS intraperitoneally or with 
      1.0 ml of it intravenously, sacrificed 24 hours later, their femoral marrows removed 
     and 105 cells were injected intravenously into lethally irradiated isogeneic female mice. 
     ALS injected mice had 20 % less number of CFU cells in their femoral marrow than 
     those injected with either NRS or Tyrode solution (Table 6: Exp. I). The mouse in-
     jected with 1 ml of ALS looked sick immediately after injection and the decrease in 
     number of CFU cells in the femoral marrow could partly be due to an indirect toxic 
     effect of ALS on the body in addition to its direct effect on lymphocytes. 
        Seven daily injections of ALS did not result in decrease of CFU cells in the femoral 
     marrow (Table 6 : Exp. II) . As stated previously, ALS is immunogenetically stronger 
     than NRS and at day 8 the mice had leucocytosis and almost normal lymphocyte count 
     as shown in Fig. 1. 
     V. Effect of ALS on circulating CFU. (Table 7) 
        Mice were injected intraperitoneally with 0.25 ml of either ALS or NRS on two 
     successive days and on the next day after the 2nd injection the mice were bled into 
     siliconized test tubes containing small amount of heparin. The blood thus obtained was 
     pooled and an aliquot injected intravenously into lethally irradiated mice. The blood of 
     mice injected with ALS contained much less number of CFU cells, the decrease being 
                         Table 7. Effect of ALS on Circulating CFU. 
         Treatment ofWBC Blood               (Lymphocytes) injected per Colony count Mean S.D.       Blood
of Donor Blood host  
Exp. I 1. ALS 0.25 ml x 2 2100 (950) 0.4 ml 1,2,0,4,4,0,0,0,0,1,1,2 1.3 1.48 
            2. NRS 0.25 ml x 2 4900 (3210) 0.4 ml 9,11,3,13,11,15,13,10,9,8 10.2 3.32 
             3. None7800 (6120) 0.4 ml 6,11,8,13,9,10,11,7,12,8,3 8.9 2.91 
                 730R irradiated control2,0,0,0,10.6 0.89
      Exp. 1. ALS 0.25 ml x 2 2600 (1160) 0.5 ml 1,1,0,2,3,0,01.0 1.15 
I I 2. NRS 0.25 ml x 2 7700 (5470) 0.5 ml 12,21,20,2319.0 4.83 
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inproportionally greater than that of lymphocyte count. 
                           DISCUSSION
   In our study the decrease of CFU cells by ALS as reported by De Meester et  a1.9) 
was essentially confirmed, although the results obtained were not identical in some details. 
The decrease was effected in the presence of complement but cytotoxic activity of ALS 
may not be the only factor concerned in the decrease of CFU cells because 1000 times 
diluted ALS and lymphocyte-absorbed ALS, both of which did not show a significant 
cytotoxicity in vitro, still had CFU decreasing activity as shown in Table 3. However, 
the problem as to whether ALS still has an anti-CFU activity after extensively absorbed 
with lymphocytes has not been studied. Studies in this respect are in progress. 
   De Meester et al.6) reported that the number of CFU cells decreased when bone 
marrow cells were incubated with ALS in the absence of complement. Their ALS 
dilution was only twice and it is not known what they did with cells probably aggregat-
ed by ALS of such a low dilution. 
   ALS decreased the number of CFU cells more readily in the peripheral blood than 
that in the bone marrow. Therefore, ALS appears not to penetrate into the hemopoie-
tic organ readily. Further, the number of CFU cells went back to normal after 7 daily 
injections of ALS. One may not necessarily be concerned much with the bone marrow 
damage during daily injections of ALS after organ homotransplantation. 
   This study clearly shows that the lymphocyte and hemopoietic stem cell have a 
common antigen. However, it is not known whether only lymphocytes possess this 
characteristics. Studies are in progress as to the antigenicity of hepatocytes and macro-
phages in order to know whether they also share a common antigen with the hemo-
poietic stem cell. 
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